48 research outputs found

    MAXIMUM VOLUME-TO-STRESS RATIO FOR A TWO-RADII-CONTOUR DIAPHRAGM PUMP

    Get PDF
    Analytical methods were employed to determine the maximum volume-to- stress ratio for a two-radii-contour diaphragm pump. A proposed failure criterion considers the effect of biaxial stresses on fatigue failure through. the use of the Mises-Hencky criterion for fatigue failure. By use of the proposed criterion, it was determined that an optimunn ratio of the two radii does exist, its value being dependent on the ratio of diphragm thickness to diaphragm deflection. Values for the optimum ratio of the two radii (where the ratio of radii is defined as the radius of the central pcrtion of the diaphragm contour divided by the radius of the outer pontion of the diaphragm) range from 1.94 to 7.33 as the ratio of diaphragm thickness to diaphragm deflection varies from 0.5 to 0.05, respectively. (auth

    Nonprofit governance: Improving performance in troubled economic times

    Get PDF
    Nonprofit management is currently pressured to perform effectively in a weak economy. Yet, nonprofit governance continues to suffer from unclear conceptions of the division of labor between board of directors and executive directors. This online survey of 114 executive directors aims to provide clarification and recommendations for social administration

    Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials

    Get PDF
    Gastrin has been shown to be a growth stimulant in pancreatic cancer cells. Gastrazole is a potent and selective gastrin receptor antagonist. Two randomised blinded trials were conducted to assess the effect of gastrazole in advanced pancreatic cancer. Patients with biopsy-proven, inoperable pancreatic carcinoma were recruited. Trial A compared protracted venous infusion (PVI) gastrazole with PVI placebo, whereas trial B compared PVI gastrazole with PVI fluorouracil (5-FU). Eighteen patients were randomised in trial A. Gastrazole produced significantly better survival compared to placebo (median 7.9 months vs 4.5 months; 1-year survival: 33 vs 11%, respectively; log rank P=0.02). No difference in toxicity was seen between gastrazole and placebo, except central venous catheter and pump complications. Ninety-eight patients were randomised in trial B. No significant survival difference was detected between gastrazole and 5-FU (median: 3.6 vs 4.2 months; 1-year survival: 13.2 vs 26.2%, respectively; log rank P=0.42). Toxicity of gastrazole was mild with significantly less diarrhoea (P=0.03), stomatitis (P<0.001) and hand– foot syndrome (P<0.001) compared to 5-FU. Quality of life (QoL) assessment showed similar QoL between gastrazole and 5-FU at baseline and no significant differences occurred with treatment either between arms or within arms. Compared to placebo, patients with advanced pancreatic cancer treated with gastrazole appeared to live longer, albeit in a very small trial and will require confirmation with large-scale randomised data. However, it did not produce survival advantage over PVI 5-FU. Lack of toxicity for gastrazole may allow its combination with cytotoxic drugs

    Neutronic calculations for a new high flux reactor

    No full text
    corecore